MedTrace Logo

Characteristics of Patients With Sickle Cell Disease

NCT05494541 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 540

Last updated 2022-11-08

No results posted yet for this study

Summary

This was a retrospective descriptive analysis of health care claims data using the IQVIA open source medical and pharmacy claims databases.

Conditions

Interventions

OTHER

Crizanlizumab

Patients who initiated crizanlizumab between November 1, 2019 and January 31, 2021 (index period) were selected into the treatment cohort.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
16 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-30
Primary Completion
2021-10-27
Completion
2021-10-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05494541 on ClinicalTrials.gov